- Home
- AGEN vs INMB Comparison
AGEN vs INMB Comparison
Compare AGEN & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- INMB
- Stock Information
- Founded
- AGEN 1994
- INMB 2015
- Country
- AGEN United States
- INMB United States
- Employees
- AGEN N/A
- INMB N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- INMB Health Care
- Exchange
- AGEN Nasdaq
- INMB Nasdaq
- Market Cap
- AGEN 96.2M
- INMB 112.0M
- IPO Year
- AGEN 2000
- INMB 2019
- Fundamental
- Price
- AGEN $2.83
- INMB $4.40
- Analyst Decision
- AGEN Buy
- INMB Strong Buy
- Analyst Count
- AGEN 3
- INMB 2
- Target Price
- AGEN $10.50
- INMB $21.00
- AVG Volume (30 Days)
- AGEN 566.5K
- INMB 215.6K
- Earning Date
- AGEN 11-12-2024
- INMB 10-31-2024
- Dividend Yield
- AGEN N/A
- INMB N/A
- EPS Growth
- AGEN N/A
- INMB N/A
- EPS
- AGEN N/A
- INMB N/A
- Revenue
- AGEN $160,427,000.00
- INMB $42,000.00
- Revenue This Year
- AGEN N/A
- INMB N/A
- Revenue Next Year
- AGEN $36.13
- INMB N/A
- P/E Ratio
- AGEN N/A
- INMB N/A
- Revenue Growth
- AGEN 59.00
- INMB N/A
- 52 Week Low
- AGEN $2.50
- INMB $4.32
- 52 Week High
- AGEN $19.69
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- AGEN 39.40
- INMB 37.57
- Support Level
- AGEN $2.65
- INMB $4.74
- Resistance Level
- AGEN $3.85
- INMB $5.16
- Average True Range (ATR)
- AGEN 0.29
- INMB 0.38
- MACD
- AGEN -0.02
- INMB -0.05
- Stochastic Oscillator
- AGEN 15.00
- INMB 5.56
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.